Novo Nordisk A/S (NVO)

As of Dec 31, 2024, Novo Nordisk A/S's fair value using the Ben Graham formula is $149.1 per share. This is calculated using Ben Graham formula, where EPS is DKK 22.7 and BVPS (Book Value Per Share) is DKK 32.2. The current price of $88.1 suggests Novo Nordisk A/S may be overvalued by this conservative metric.

Novo Nordisk A/S earnings per share (EPS) for the twelve months ending Dec 31, 2024, was DKK 22.7, a 23.5% growth year-over-year.

Novo Nordisk A/S's margin of safety is positive 69.3%, calculated as (Graham Number - Current Price) / Current Price. A negative margin of safety suggests the stock doesn't provide the level of safety Graham typically sought in his investments.